Autoimmune

Autoimmune Hepatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Autoimmune Hepatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Autoimmune Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autoimmune Hepatitis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, co...

$2,000.00

Autoimmune Disease Diagnostic Market, By Disease, Tests Type, Regions, Global Forecast

Wed, 20 May 2020 11:34:50 +0000

Autoimmune disease refers to disease where immune system produces antibodies that kill or attack healthy cells or tissues. The immune system work is to provide protection against germs such as bacteria and virus. In autoimmune disease immune system wrongly attacks patients body. According to American Autoimmune Related Diseases Association, autoimmune disease affects fifty million Americans in which 25% are male and 75% are female. The Global Autoimmune Disease Diagnostic Market is expected to surpass US$ 18 Billion by the year end of 2025.

Although there are 80 Types of Autoimmune Diseases, but 14 most Common Autoimmune Diseases are as follows:

Rheumatoid Arthritis, Psoriasis/psoriatic arthritis, Multiple sclerosis, Type 1 diabetes, Inflammatory bowel disease, Systemic Lupus Erythematosus (SLE), Addison’s disease, Sjögren’s syndrome, Graves’ disease, Hashimoto’s thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Celiac disease, Pernicious anemia.

Factors Driving the Autoimmune Disease Diagnostic Market

Rising technological advance...

$1,995.00

Global Autoimmune Disease Diagnostic Market (By Disease, Tests Type, Regions), Key Company Profiles - Forecast to 2026

Wed, 20 May 2020 11:05:38 +0000

The global autoimmune disease diagnostics market is expected to reach nearly US$ 18 Billion by 2026. Autoimmune diseases refer to a body’s abnormal immune response leading to production of antibodies that attack own cells and tissues, causing deterioration and destruction of healthy tissues. Autoimmune diseases can be divided into two general groups: Organ specific, where the autoantibodies attack a specific organ, and Non-organ specific (or systemic), where the autoantibodies attack multiple organ systems. There are almost 80 types of autoimmune diseases prevailing worldwide including systemic lupus erythematosus or rheumatoid arthritis. As per the American Autoimmune Related Diseases Association, around 50 million Americans currently suffer from autoimmune related disorders. Moreover, the numbers are expected to escalate over the forecast period. The demand for better and precise diagnostic methods, along with the increasing prevalence, is expected to increase over the forecast period. The tests used to diagnose the autoimmune disease include auto antibody test, antinuclear antib...

$1,890.00

Acquired (Autoimmune) Hemolytic Anemia Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acquired (Autoimmune) Hemolytic Anemia Global Clinical Trials Review, H2, 2018" provides an overview of Acquired (Autoimmune) Hemolytic Anemia clinical trials scenario. This report provides top line data relating to the clinical trials on Acquired (Autoimmune) Hemolytic Anemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities an...

$2,500.00

Autoimmune Drugs Markets in China

Wed, 09 May 2018 11:25:43 +0000

China's demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are condu...

$4,000.00

Autoimmune Drugs Industry Forecasts - China Focus

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Autoimmune Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovatio...

$1,800.00

Autoimmune Drugs Companies in China

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Autoimmune Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering...

$1,800.00

Autoimmune Hepatitis Global Clinical Trials Review, H2, 2016

Wed, 11 Jan 2017 15:23:53 +0000

Summary

GlobalData's clinical trial report, “Autoimmune Hepatitis Global Clinical Trials Review, H2, 2016" provides an overview of Autoimmune Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Autoimmune Hepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to g...

$2,500.00

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

Thu, 06 Oct 2016 11:26:22 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Autoimmune Haemolytic Anaemia (AIHA) in 8 Major Markets Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition. This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AIHA’s have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities for AIHA...

$6,400.00

Guillain-Barre Syndrome (GBS)-Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Guillain-Barre Syndrome (GBS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Guillain-Barre Syndrome (GBS) for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Guillain-Barre Syndrome (GBS) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Guillain-Barre Syndrome (GBS) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Guillain-Barre Syndrome (GBS) market. • Identifying patient populations in the global “Guillain-Barre Syndrome (GBS) market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best op...

$4,950.00

Pemphigus Vulgaris - Pipeline Review, H1 2016

Fri, 17 Jun 2016 09:15:01 +0000

Summary

Global Markets Direct’s, ‘Pemphigus Vulgaris - Pipeline Review, H1 2016’, provides an overview of the Pemphigus Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, ...

$2,000.00